Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck Millipore Publishes White Paper

Published: Wednesday, February 27, 2013
Last Updated: Wednesday, February 27, 2013
Bookmark and Share
Details use of flow cytometry and surface plasmon resonance to quantify binding of therapeutic monoclonal antibodies to molecules mediating cytotoxicity.

Merck Millipore has announced the publication of a white paper, "Effective In Vitro Bioanalytical Assays for Comparing Pharmacodynamics of Biosimilar Monoclonal Antibodies", which describes both regulatory and technical aspects of comparability studies for the development of biosimilars.

The white paper describes two bioanalytical approaches involving measurements of ligand binding to compare pharmacodynamics of biosimilars.

Specifically, surface plasmon resonance (SPR) and flow cytometry were used to quantify the binding of two therapeutic mAbs, alemtuzumab and infliximab, to molecules mediating cytotoxicity. Data generated from these comparability studies are highlighted.

The biosimilar therapeutics industry, estimated to be greater than $90 billion, is rapidly expanding and poised to see dramatic growth in the next five years in the United States, Europe and other international markets.

This explosion is being driven by the large size of the biologics industry, upcoming patent expirations on many major branded biologics and the issue of new or updated regulatory guidelines by the FDA, EMA and DBT of India.

While the industry is growing rapidly, developing a biosimilar therapeutic can be expensive, as each new biosimilar must prove that variances from the innovator drug are not clinically significant.

Therefore, there is a critical need for accurate and precise nonclinical, in vitro assays to measure drug potency.

"Although our regulatory bioanalytical services were founded on supporting the development of innovator biologics, we have also helped lead the development of both simple peptide and complex monoclonal antibody biosimilars," says James Hulse, Ph.D., Managing Scientific Director of Discovery and Development Solutions.

Hulse continued, "The regulatory guidelines governing the development of biosimilars are relatively new, and this white paper describes new approaches for development of preclinical data about drug properties and their physiological interactions without the need for animal experiments."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Millipore Announces Agreement with Precision Biologics
Merck Millipore services include design and development of cost-effective process to deliver high yield and productivity.
Thursday, February 05, 2015
Merck Millipore Expands Biomanufacturing Sciences and Training Center in Japan
Facility expansion and relocation of existing operations from Yokohama, Kanagawa Prefecture to Tokyo.
Thursday, August 28, 2014
Merck Millipore Invests €12M in France Facility
The investments will expand ready-to-use media manufacturing at company's Molshiem facility.
Tuesday, August 12, 2014
Merck Millipore Announces Incoming CEO and President
Udit Batra, Ph.D. will be responsible for the organization’s strategic direction to drive growth and product innovation as well as oversight of the worldwide operations.
Tuesday, April 15, 2014
Merck Millipore Announces Co-marketing Agreement with groninger
Offering combines industry-leading single-use assemblies, sterility assurance solutions and stainless steel filling equipment.
Tuesday, August 13, 2013
Merck KGaA Passes EXCiPACT Audit for Certification as Provider of Pharmaceutical Excipients
Ensures current GMP and GDP requirements applied to pharmaceutical excipients through a recognized auditing and certification process.
Friday, August 02, 2013
Merck Millipore Announces Opening of its GMP Bioproduction Facility in France
Enables accelerated process development and production of proteins/monoclonal antibodies.
Friday, September 21, 2012
Merck Millipore Announces Exclusive Agreement with Julphar Diabetes
Collaboration to offer non-animal origin, recombinant human insulin as cell culture media supplement.
Wednesday, August 08, 2012
Andrew Bulpin to Assume Leadership of Process Solutions at Merck Millipore
Bulpin appointed as head of the company's process solutions business unit.
Wednesday, May 02, 2012
Merck Millipore and CCRM Collaborate to Optimize Conditions for Large-scale Stem Cell Cultivation
Collaboration to deliver optimized methodologies for cultivation of stem cells on microcarriers in Mobius® CellReady bioreactor systems.
Tuesday, March 13, 2012
Scientific News
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!